289 related articles for article (PubMed ID: 23094824)
1. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.
Subramaniam K; D'Rozario J; Pavli P
J Gastroenterol Hepatol; 2013 Jan; 28(1):24-30. PubMed ID: 23094824
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle.
Sokol H; Beaugerie L
Gut; 2009 Oct; 58(10):1427-36. PubMed ID: 19749141
[TBL] [Abstract][Full Text] [Related]
3. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
4. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
5. Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications.
Subramaniam K; Cherian M; Jain S; Latimer M; Corbett M; D'Rozario J; Pavli P
Intern Med J; 2013 Dec; 43(12):1339-42. PubMed ID: 24330365
[TBL] [Abstract][Full Text] [Related]
6. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
Magro F; Peyrin-Biroulet L; Sokol H; Aldeger X; Costa A; Higgins PD; Joyce JC; Katsanos KH; Lopez A; de Xaxars TM; Toader E; Beaugerie L
J Crohns Colitis; 2014 Jan; 8(1):31-44. PubMed ID: 23721759
[TBL] [Abstract][Full Text] [Related]
7. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
8. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study.
Vos AC; Bakkal N; Minnee RC; Casparie MK; de Jong DJ; Dijkstra G; Stokkers P; van Bodegraven AA; Pierik M; van der Woude CJ; Oldenburg B; Hommes DW;
Inflamm Bowel Dis; 2011 Sep; 17(9):1837-45. PubMed ID: 21830262
[TBL] [Abstract][Full Text] [Related]
9. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
[TBL] [Abstract][Full Text] [Related]
10. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
11. EBV Status and Thiopurine Use in Pediatric IBD.
Gordon J; Ramaswami A; Beuttler M; Jossen J; Pittman N; Lai J; Dunkin D; Benkov K; Dubinsky M
J Pediatr Gastroenterol Nutr; 2016 May; 62(5):711-4. PubMed ID: 26655944
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus related lymphoma in inflammatory bowel disease.
Van Biervliet S; Velde SV; De Bruyne R; De Looze D; De Vos M; Van Winckel M
Acta Gastroenterol Belg; 2008; 71(1):33-5. PubMed ID: 18396748
[TBL] [Abstract][Full Text] [Related]
13. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
[TBL] [Abstract][Full Text] [Related]
14. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
[TBL] [Abstract][Full Text] [Related]
15. [Inflammatory bowel disease and lymphoproliferative disorders].
Ye BD
Korean J Gastroenterol; 2011 Oct; 58(4):171-7. PubMed ID: 22042416
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression-related lymphomas and cancers in IBD: how can they be prevented?
Beaugerie L
Dig Dis; 2012; 30(4):415-9. PubMed ID: 22796808
[TBL] [Abstract][Full Text] [Related]
17. [Lymphoproliferative disorders in an inflammatory bowel disease unit].
Van Domselaar M; López San Román A; Bastos Oreiro M; Garrido Gómez E
Gastroenterol Hepatol; 2010 Jan; 33(1):12-6. PubMed ID: 19889478
[TBL] [Abstract][Full Text] [Related]
18. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.
Kwon JH; Farrell RJ
Crit Rev Oncol Hematol; 2005 Oct; 56(1):169-78. PubMed ID: 15979323
[TBL] [Abstract][Full Text] [Related]
19. Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
Thai A; Prindiville T
J Crohns Colitis; 2010 Nov; 4(5):511-22. PubMed ID: 21122554
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders.
Nissen LH; Nagtegaal ID; de Jong DJ; Kievit W; Derikx LA; Groenen PJ; van Krieken JH; Hoentjen F
J Crohns Colitis; 2015 May; 9(5):398-403. PubMed ID: 25740811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
